Orphan Drugs for AML Industry 2018 – Company Profile, SWOT Analysis, Size, Share, Growth, Trends and Forecast

“\”Orphan Drugs for AML Market\””
WiseGuyReports.com adds “Orphan Drugs for AML Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting ”reports to its database.

Orphan Drugs for AML Market:

Executive Summary

Adroit Healthcare Services ‘Orphan drugs for AML – Competitive Landscape and Market, Market Access Potential, Pricing & Pipeline Analysis, 2018’ provides the comprehensive list of orphan drugs that are indicated for acute myeloid leukemia. The main objective of this report is to provide a comprehensive secondary research and market analysis of orphan drugs that are indicated for treating acute myeloid leukemia. This report also includes the market access and reimbursement challenges across EU5 and US. With Vidaza indicated as standard of care and the low dose cytabine indicated as well (off label), there are opportunities and challenges involved in the new drug development. Understanding the market access challenges of the recently approved drugs, there are many key takeaways which are presented in the current report. This report also includes the pipeline products that are in Phase 3, Phase 2, Phase 1, & preclinical stage of development. This report also provides comprehensive research on the companies that are working on AML inhibitors including the deals and acquisitions.

The report is built with the in-depth secondary research, understanding the market access aspects across the different countries.

  • Noventia Pharma Srl
  • Janssen-Cilag International N V
  • Ariad Pharma Ltd
  • Novartis Europharm Ltd
  • Celgene Europe Limited
  • Otsuka Pharmaceuticals
  • Daiichi-Sankyo
  • Arog pharmaceuticals
  • Cyclacel pharmaceuticals
  • Sunesis pharmaceuticals
  • Boehringer Ingelheim
  • Onconova
  • Sanofi

Request Sample Report @ https://www.wiseguyreports.com/sample-request/3077000-orphan-drugs-for-aml-competitive-landscape-and-market

Table of Content

1. Disease Landscape 
    1.1 Acute Myeloid Leukemia 
    1.2 Etiology and Pathophysiology 
    1.3 Key findings 
    1.4 Disease overview 
    1.5 Etiology 
    1.6 Pathogenesis 
    1.7 Key pathways and drug targets 
2. Key updates: 
• March 2018 
• December 2017 
• September 2017 
3. Executive summary 
    3.1 Key findings 
4. Market Outlook 
    4.1 Key findings 
    4.2 Market drivers and constraints 
    4.3 SWOT analysis 
5. Orphan drug 
    5.1 US orphan drug approval 
    5.2 EU orphan drug approval 
    5.3 Japan orphan drug approval 
6. Epidemiology Overview 
    6.1 Introduction Key Findings 
    6.2 Epidemiology populations total prevalent cases 
7. Current treatment overview 
    7.1 Key findings 
    7.2 Orphan drugs available to treat AML 
    7.3 Product specific page 
      7.3.1 Ceplene 
      7.3.2 Dacogen 
      7.3.3 Iclusig 
      7.3.4 Rydapt 
      7.3.5 Vidaza 
8. Companies working on AML drugs 
    8.1 Collaborations, deals and acquisitions 
9. Emerging treatment overview 
    9.1 Key findings 
    9.2 Late stage products 
    9.3 Phase 2 products 
    9.4 Early state products 
10. Access and Reimbursement Overview 
    10.1 Region-Specific Reimbursement Practices 
      10.1.1 United states 
      10.1.2 EU5 
11. Appendix 
Table 1: US and EU drug approvals for Orphan drugs 
Table 2: Orphan drugs available to treat AML 
Table 3: Comparative HTA opinions 
Table 4: Collaborations, deals and acquisitions 
Table 5: Late stage products 
Table 6: Phase 2 products 
Figure 1: US and EU drug approvals for Orphan drugs 
Figure 2: Orphan drugs available to treat AML 
Figure 3: Comparative HTA opinions 
Figure 4: Pricing of drugs that are indicated for AML 
Figure 5: Late stage products 
Figure 6: Phase 2 products 
Figure 7: Assessment based on route of administration 
Figure 8: Assessment by molecule type


For further information on this report, visit – https://www.wiseguyreports.com/reports/3077000-orphan-drugs-for-aml-competitive-landscape-and-market


Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com